Fresenius signs biosimilars pipeline agreement with WuXi Biologics

Fresenius SE & Co. KGaA

Mon 06:16

Nov 2 (Reuters) - Fresenius FREn.DE has signed a biosimilars development agreement with China's WuXi Biologics 2269.HK, the German healthcare group said on Monday.
The agreement gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade, addressing more than €370 billion ($414 billion) in originator sales, it added.
($1 = 0.8948 euros)

(Reporting by Tristan Veyet and Kira Britten in Gdansk, editing by Milla Nissi-Prussak)
((Tristan.veyet@thomsonreuters.com ))